Versartis, Inc. (NASDAQ:VSAR) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
Spokespersons of Versartis, Inc. (the Company) presented the
information in the presentation poster attached hereto as Exhibit
99.1 at the 28th Annual Piper Jaffray Healthcare Conference in
New York City, New York on November 29, 2016.
The furnishing of the attached presentation is not an admission
as to the materiality of any information therein. The information
contained in the poster is summary information that is intended
to be considered in the context of more complete information
included in the Companys filings with the Securities and Exchange
Commission (the SEC) and other public announcements that the
Company has made and may make from time to time by press release
or otherwise. The Company undertakes no duty or obligation to
update or revise the information contained in this report,
although it may do so from time to time as its management
believes is appropriate. Any such updating may be made through
the filing of other reports or documents with the SEC, through
press releases or through other public disclosures.
The information in this Item 7.01 of this Current Report on Form
8-K and Exhibit 99.1 attached hereto shall not be deemed filed
for purposes of Section 18 of the Securities Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in any such filing.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit is furnished with this Current Report on
Form 8-K.
|
Exhibit No. |
Description |
|
|
99.1 |
Company poster presentation dated November 2016. |
|
About Versartis, Inc. (NASDAQ:VSAR)
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals. Versartis, Inc. (NASDAQ:VSAR) Recent Trading Information
Versartis, Inc. (NASDAQ:VSAR) closed its last trading session down -0.10 at 12.50 with 78,987 shares trading hands.
